Trial Profile
Safety, tolerability, pharmacokinetics, and pharmacodynamics of hyzetimibe (HS-25) in healthy Chinese subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Hyzetimibe (Primary)
- Indications Hypercholesterolaemia; Hyperlipidaemia
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Zhejiang Hisun Pharmaceutical
- 20 Dec 2021 Data from this study used to develop a PopPK model of f HS-25 published in the British Journal of Clinical Pharmacology
- 17 Dec 2015 New trial record